BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions

Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma

The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability

FDA approves Alembic's Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients

Sai Life Sciences to double process R&D capacity with new facility in Hyderabad

The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization

MilliporeSigma partners with Promega to advance 3-D cell drug discovery technologies

Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies

Zydus receives approval from Health Canada for Mesalamine suppositories

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis

CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors

The event will be attended by 35,000+ industry professionals

Sanofi's Q3 profit dips marginally as Dupixent sales top €4 billion

The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year

Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study

Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy